Published: Thu, May 11, 2017
Business | By Max Garcia

Pfizer strikes deal with Sangamo, broadening hemophilia pipeline

Pfizer strikes deal with Sangamo, broadening hemophilia pipeline

Analysts have a mean recommendation of 1.80 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Tocqueville Asset Management L.P. now owns 390,915 shares of the biopharmaceutical company's stock valued at $2,033,000 after buying an additional 143,250 shares during the period. Candriam Luxembourg S.C.A. now owns 270,000 shares of the biopharmaceutical company's stock valued at $1,404,000 after buying an additional 70,000 shares during the period. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.12. The stock's market cap is $308.31 million.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 38.57% over the past 6 months and is uptrending.

Total shares held by institutions as of the most recent company filings are 38,842,596 with a reported 2,393,938 bought and 4,577,499 sold. The institutional investor owned 61,070 shares of the biopharmaceutical company's stock at the end of the fourth quarter. The current share price indicates that stock is -42.76% away from its one year high and is moving 64.15% ahead of its 52-week low. The correct version of this story can be viewed at The company's 50-day moving average price is $4.46 and its 200 day moving average price is $3.91. Wedbush reaffirmed a "neutral" rating and issued a $4.00 target price on shares of Sangamo Therapeutics in a research note on Wednesday, February 8th. 1,057,634 shares of the company's stock were exchanged. Altrinsic Global Advisors LLC raised its position in shares of Sangamo Therapeutics by 26.0% in the third quarter. Sangamo Therapeutics had a negative net margin of 388.23% and a negative return on equity of 45.02%.

But speaking to FierceBiotech at the start of the year, Bioverativ's new chief and former Biogen exec John Cox told me that while they are to working on gene therapy approaches to hemophilia, there are reasons to be cautious: "There are of course question marks over gene therapy: The obvious one is safety, because of the history here, and this is a risk-averse population, for good reason, and the other question is naturally over efficacy, and how long does it last, as well as manufacturing, scale and so on". First quarter 2017 revenues were generated from Sangamo's collaboration agreements with Bioverativ, Shire International (Shire) and Sigma-Aldrich, enabling technology agreements and research grants. The stock presently has a consensus rating of "Hold" and an average price target of $7.75. Similarly, the company guided revenue between $1.185 and $1.215 billion while analysts look for $1.271 billion. If you are accessing this story on another publication, it was copied illegally and reposted in violation of USA and global trademark and copyright legislation.

About Sangamo Therapeutics Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company.

Gene therapy is a potentially transformational technology for patients, focused on highly specialized, one-time, treatments that address the root cause of diseases caused by genetic mutation.

Like this: